Abstract
This chapter is devoted to the formulation and analysis of several models of the VEGF receptor and the initial steps in the signalling cascade following receptor activation. Our models take into consideration different factors and processes such as receptor cross-linking, endocytosis, recycling, degradation and synthesis. The effect of each one of these factors is studied. In particular, we present an analysis of a stochastic model of the vascular endothelial growth factor (VEGF) receptor, which accounts for ligand binding-induced oligomerisation, activation of SH2 domain-carrying kinases and receptor internalization. This is an analysis, based upon a generalisation of a WKB approximation of the solution of the corresponding Master Equation, of the role and contribution of each of these processes to the overall behaviour of the VEGF/VEGF receptor (VEGFR) system. The results of this analysis, in turn, allow us to formulate plausible mechanisms for tumour resistance to antiangiogenic therapy. We predict that tumour-mediated overexpression of VEGFRs in the endothelial cells (ECs) of tumour-engulfed vessels leads to an increased sensitivity of the ECs to low concentrations of VEGF, thus endowing the tumour with increased resistance to antiangiogenic treatment. We then show using a simplified version of the above model, that it exhibits different dynamical behaviours, which account for different cell responses to stimulation with growth factor, from perfect adaptation to sustained response thus providing a framework which attempts to understand how a single sensorial system can produce a variety of different responses.
Keywords
- Vascular Endothelial Growth Factor
- Vascular Endothelial Growth Factor Receptor
- Vascular Endothelial Growth Factor Concentration
- Receptor Endocytosis
- Receptor Tyrosine Kinase Activation
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
These three types of VEGFR are surface receptors. There is also a soluble form of VEGFR-1.
- 2.
Throughout the paper, we use the same covention: an upper-case letter represents numbers of molecules of a given type, whereas the corresponding lower-case letter represents the proportion of molecules of that particular kind with respect to the total number of molecules. An exception to this rule is L, whose meaning is explained in the text.
- 3.
Teis and Huber (2003) distinguish between active and inactive RTKs. We will assume that “active” refers to dimerised receptors, which seems to be pretty clear from the context, and that “inactive” refers to both unbound receptors and non-dimerised ligand/receptor complexes.
- 4.
Within the statistical physics community, this approximation is often referred to as the eikonal approximation.
- 5.
Kubo et al. (1973) states the multidimensional result without a proof.
- 6.
- 7.
In fact, this method produces a hierarchy of “kinetic” equations where the cumulants of order n depend on the all the cumulants of order up to n − 1.
References
Alarcón, T. and Page, K.M. (2006). Stochastic models of receptor oligomerisation by bivalent ligand. J. R. Soc. Interface. 3, 545-559.
Alarcón, T. and Page, K.M. (2007). Mathematical models of the VEGF receptor and its role in cancer therapy. J. R. Soc. Interface. 4, 283-304.
Autiero, M., Waltenberg, J., Communi, D., Kranz, A., Moons, L., Lambrechts, D., Kroll, J., Plaisance, S., De Mol, M. Bono, F., Kilche, S., Fellbrich, G., Ballmer-Hofer, K., Maglione, D., Mayer-Beyrle, U., Dewerchin, M., Dombrowski, S., Stanimirovic, D., Van Hummelen, P., Heio, C., Hicklin, D.J., Persico, G., Herbert, J.M., Shibuya, M., Collen, D., Conway E.M., Carmeliet, P. (2003). Role of PIGF in the intra- and inter-molecular cross-talk between the VEGF receptor Flt1 and Flk1. Nat. Med. 9. 936-943.
Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., Walter, P. (2002). Molecular biology of the cell. Garland Publishing, New York, NY (USA).
Alon, U., M.G. Surette, N. Barkai, S. Leibler. (1999). Robustness in bacterial chemotaxis. Nature. 347, 168-171.
Amlal, H., Faroqui, S., Balasubramaniam, A., and Sheriff, S. (2006). Estrogen up-regulates neuropeptide YY1 receptor expression in a human breast cancer cell line. Cancer Res. 66, 3706-3714.
Berger, G., and Benjamin, L.E. (2003). Tumorigenesis and the angiogenic switch. Nature Rev. Cancer. 3, 401-410.
Cai, J., Jians, W.G., Ahmed, A. and Bulton, M. (2006). Vascular endothelial growth factor induced cells proliferation is regulated by interaction between VEGFR-s, SH-PTP1 and eNOS. Microvasc. Res. 71, 20-31.
Cross, M.J., Dixelius, J., Matsumoto, T., and Claesson-Welsh, L. (2003). VEGF-receptor signal transduction. Trends Biochem. Sci. 28, 488-494.
Dixelius, J., Makinen, T., Wirzenius, M., Karkkainen, M.J., Wernstedt, C., Alitalo, K., Claesson-Welsh, L. (2003). Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerisation with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J. Biol. Chem. 278, 40973-40979.
Ebens, A., K. Brose, E.D. Leonardo, M.G. Hanson, F. Bladt, C. Birchmeier, B.A. Barres, M. TessierLavigne. (1996). Hepatocyte growth factor scatter factor is an axonal chemoattractant and a neurotrophic factor for spinal motor neurons. Neuron. 17, 1157-1172.
Felder, S., Zhou, M., Hu, P., Urena, J., Ullrich, A., Chaudhuri, M., White, M., Shoelson, S.E., and Schlessinger, J. (1993). SH2 domains exhibit high affinity binding to tyrosine-phosphorylated peptides yet al.so exhibit rapid dissociation and exchange. Mol. Cell. Biol. 13, 1449-1455.
Ferrara, N. (2002). Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. 29 (6 Suppl. 16), 10-14.
Grotendorst, G.R., Chang, T., Seppa, H.E., Kleinman, H.K., and Martin, G.R. (1982). Platelet-derived growth factor is a chemoattractant for vascular smooth muscle cells. J. Cell Physiol. 113, 261-266.
Hampton, T. (2005). Antiangiogenic therapy a two-trick pony? JAMA. 293, 1051.
Helmreich, E.J.M. (2001). The biochemistry of cell signalling. Oxford University Press, New York, NY (USA).
Hicklin, D.J., and Ellis, L.M. (2005). Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23, 1011-1027.
Holash, J., Wiegand, S.J., Yancopoulos, G.D. (1999). New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene. 18, 5356-5362.
Jain, R. (2005). Normalization of tumour vasculature: an emerging concept in antiangiogenic therapy Science. 307, 58-62.
Kitahara, K. (1973). The Hamilton-Jacobi equation approach to fluctuation phenomena Adv. Chem. Phy. 29, 85-111.
Klominek, J., Baskin, B., and Hauzenberger, D. (1998). Platelet-derived growth factor (PDGF) BB acts as a chemoattractant for human malignant mesothelioma cells via PDGF receptor β-integrin α3β1 interaction. Clin. Exp. Metastasis. 16, 529-539.
Knox, B.E., P.N. Devreotes, A. Goldbeter, L.A. Segel. (1986). A molecular mechanism for sensory adaptation based on ligand-induced receptor modification Proc. Nat. Acad. Sci. 83, 2345-2349.
Kubo, R., Matsuo, K., and Kitahara, K. (1973). Fluctuation and relaxation of macrovariables J. Stat. Phys. 9, 51-96.
Lauffenburger, D.A., and Linderman, J.J. (1993). Receptors: models for binding, trafficking, and signalling. Oxford University Press, New York, (USA).
Lash, G.E., A.Y. Warren, S. Underwood, P.N. Baker. (2003). Vascular endothelial growth factor is a chemoattractant for trophoblast cells. Placenta. 24, 549-556.
Levchenko, A., P.A. Iglesias. (2002). Models of eukaryotic gradient sensing: application to chemotaxis of amoebae and neutrophils. Biophys. J. 82, 50-63.
Mac Gabham, F., and Popel, A.S. (2004). Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 286, H153-H164.
Mac Gabham, F., and Popel, A.S. (2005a). Differential binding of VEGF isoforms to VEGF receptor 2 in the presence of neuropilin-1: a computational model. Am. J. Physiol. Heart Circ. Physiol. 288, H2851-H2860.
Mac Gabham, F., and Popel, A.S. (2005b). Monte Carlo simulations of VEGF binding to cell surface receptors in vitro. Biochim. Biophys. Acta – Mol. Cell Res. 1746, 95-107.
Marshall, C.J. (1995). Specifity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell. 80, 179-185.
Mitchell, H., A. Chowdhury, R.E. Pagano, E.B. Leof. (2004). Ligand-dependent and -independent tranforming growth factor-β receptor recycling regulated by clathrin-mediated endocytosis and Rab11. Mol. Biol. Cell. 15, 4166-4178.
Ohshima, M., Y. Noguchi, Y. Ito, M. Maeno, K. Otsuka. (2001). Hepatocyte growth factor secreted by periodontal ligament and gingival fibroblasts is a major chemoattractant for gingival epithelial cells. J. Periodontal Res. 36, 377-383.
Park, C.H, Schneider, I.C., and Maugh, J.M. (2003). Kinetic analysis of platelet-derived growth factor receptor/phosphoinositide 3-kinase/Akt signalling in fibroblast. J. Biol. Chem. 278, 37064-37072.
Polo, S., Pece, S., and Di Fiore, P.P. (2004). Endocytosis and cancer. Curr. Opin. Cell Biol. 16, 156-161.
Posner, R.G., Wofsy, C., and Goldstein, B. (1995). The kinetics of bivalent ligand-bivalent receptor aggregation: Ring formation and the breakdown of equivalent site approximation Math. Biosciences. 126, 171-190.
Reibman, J., S. Meixler, T.C. Lee, L.I. Gold, B.N. Cronstein, K.A. Haines, S.L. Kolasinski, G. Weissmann. (1991). Transforming growth factor β1, a potent chemoattractant for human neutrophils, bypasses classic signal-transduction pathways. Proc. Nat. Acad. Sci. 88, 6805-6809.
Sasagawa, S., Y. Ozaki, K. Fujita, S. Kuroda. (2005). Prediction and validation of the distinct dynamics of transient and sustained ERK activation. Nature Cell Biol. 7, 365-373.
Sawada, J., A. Itakura, A. Tanaka, T. Furusaka, H. Matsuda. (2000). Nerve growth factor functions as a chemoattractant for mast cells through both mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling pathways. Blood. 95, 2052-2058.
Sawyer, T.K. (1998). Src homology-2 domains: Structure, mechanisms and drug discovery. Biopolymers. 47 243-261.
Schlesinger, J., D. Bar-Sagi. (1995). Activation of Ras and other signalling pathways by tyrosine kinase receptors. In Symposia on Quantitative Biology: Molecular Genetics and Biology. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, USA).
Schneider, I.C., J.M. Haugh. (2005). Quantitative elucidation of a distinct spatial gradient-sensing mechanism in fibroblasts. J. Cell Biol. 171, 883-892.
Shibuya, M., Claesson-Welsh, L. (2006). Signal transduction by VEGF receptors in regulation of angiogenesis and lymphoangiogenesis. Exp. Cell Res. 312, 549-560.
Spiro, P.A., J.S. Parkinson, H.G. Othmer. (1997). A model for excitation and adaptation in bacterial chemotaxis. Proc. Nat. Acad. Sci. 94, 7263-7268.
Sulzer, B., De Boer, R.J., and Perelson, A.S. (1996). Cross-linking reconsidered: binding and cross-linking fields and the cellular response. Biophys. J. 70, 1154-1168.
Suzuma, I., Mandai, M., Takagi, H., Suzuma, K., Otani, A., Oh, H., Kobayashi, K., and Honda, Y. (1999). 17 β-estradiol increases VEGF receptor-2 and promotes DNA synthesis in retinal microvascular endothelial cells. Invest. Ophth. Vis. Sci. 40, 2122-2129.
Teis, D., and Huber, L.A. (2003). The odd couple: signal transduction and endocytosis. Cell. Mol. Life Sci. 60, 2020-2033.
Terranova, V.P., DiFlorio, R., Lyall, R.M., Hic, S., Friesel, R., and Maciag, T. (1985). Human endothelial cells are chemotactic to endothelial cell growth factor and heparin. J. Cell Biol. 101, 2330-2334.
Traverse, S., K. Seedorf, H. Patterson, C.J. Marshall, P. Cohen, A. Ullrich. (1994). EGF triggers neuronal differentiation of PC12 cells that overexpress EGF receptor. Curr. Biol. 4, 694-701.
Tyson, J.J., Chen, K.C., and Novak, B. (2003). Sniffers, buzzers, toggles and blinkers: dynamics and signalling pathways in the cell. Curr. Opin. Cell Biol. 15, 221-231.
Van Kampen, N. (1992). Stochastic processes in physics and chemistry. North-Holland, Amsterdam.
Vaudry, D., P.J.S. Stork, P. Lazarovici, L.E. Eiden. (2002). Signalling pathways for PC12 cell differentiation: making the right connections. Science. 296, 1648-1649.
Vilar, J.M.G., Jansen, R., and Sander, C. (2006). Signal processing in the TGF-β superfamily ligand receptor network. PLOS Comput. Biol. 2, 36-45.
Wiley, H.S., J.J. Herbst, B.J. Walsh, D.A. Lauffenburger, M.G. Rosenfeld. (1991). The role of receptor tyrosine kinase activity in endocytosis, compartmentation and down-regulation of the epidermal growth factor receptor. J. Biol. Chem. 266, 11083-11094.
Woolf, P.J., and Linderman, J.J. (2004). An algebra of dimerisation and its implications for G-protein coupled receptor. J. theor. Biol. 229, 157-168.
Yaka, R., A. Gamliel, D. Gurwitz, R. Stein. (1998). NGF induces transient but not sustained activation of ERK in PC12 mutant cells incapable of differentiating. J. Cell. Biochem. 70, 425-432.
Yi, T.-M., Y. Huang, M.I. Simon, J. Doyle. (2000). Robust perfect adaptation in bacterial chemotaxis through integral feedback control. Proc. Nat. Acad. Sci. 97, 4649-4653.
Ti Zhang, Hui-Chuan Sun, Yang Xu, Ke-Zhi Zhang, Lu Wang, Lun-Xiu Qin, Wei-Zhong Wu, Yin-Kun Liu, Sheng-Long Ye, and Zhao-You Tang. (2005). Overexpression of PDGF Receptor α in endothelial cells of hepatocellular carcinoma associated with metastatic potential. Clin Cancer Res. 11, 8557-8563.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Alarcón, T., Page, K.M. (2012). Mathematical Modeling of the VEGF Receptor. In: Jackson, T.L. (eds) Modeling Tumor Vasculature. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-0052-3_1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-0052-3_1
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-0051-6
Online ISBN: 978-1-4614-0052-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)